California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and clinical-stage life sciences companies. The Vivo Opportunity Fund is an evergreen public ...
The city of Boston remains top dog when it comes to biotechnology and scientific innovation, beating out longtime biotech powerhouses like San Francisco, San Diego and Washington, D.C. With more than ...
PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical in muscle wasting and lean mass imbalance, aiming to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results